Exposure-biomarker analyses for cytokine release syndrome or infusion-related reaction, pain, and cytokine concentrations in serum during treatment with ubamatamab, a MUC16xCD3 bispecific antibody, among patients with recurrent ovarian cancer

被引：0

作者：

Madia, Priyanka ^{[1
]}

Brouwer-Visser, Jurriaan ^{[1
]}

Qin, Qiao ^{[1
]}

Conrado, Daniela ^{[1
]}

Davis, John ^{[1
]}

Uldrick, Thomas ^{[1
]}

Peterman, Mary ^{[1
]}

Miller, Elizabeth ^{[1
]}

Zhu, Min ^{[1
]}

机构：

[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2129

引用

页码：S287 / S287

页数：1

共 9 条

[1] Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results
Liu, Joyce
O'Malley, David
Van Nieuwenhuysen, Els
Moore, Kathleen
Hamilton, Erika
Yeku, Oladapo
Bouberhan, Sara
Hou, June
Schroeder, David
Wang, Bin
Yoo, Suk-Young
Govindraj, Shilpa
Brouwer-Visser, Jurriaan
Peterman, Mary
Schmidt, Tamara
Barnes, Brigid
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
O'Cearbhaill, Roisin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A9 - A10
[2] First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen N.
Bouberhan, Sara
Hamilton, Erika P.
Liu, Joyce F.
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
Papadamitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Peterman, Mary Jane
Goncalves, Priscila Hermont
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Van Nieuwenhuysen, E.
O'Malley, D.
O'Cearbhaill, R. E.
Moore, K. N.
Hamilton, E. P.
Yeku, O.
Bouberhan, S.
Hou, J. Y.
Yoo, S-Y.
Brouwer-Visser, J.
Cheung, H. K.
Peterman, M.
Goncalves, P.
Schmidt, T.
Zhu, M.
Lowy, I.
Rowlands, T.
Uldrick, T. S.
Miller, E. A.
Liu, J. F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S784 - S784
[4] First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen
Bouberhan, Sara
Hamilton, Erika
Liu, Joyce
O'Cearbhaill, Roisin
O'Malley, David
Papadimitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Goncalves, Priscila
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A254 - A255
[5] EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)
Madia, P.
Conrado, D.
Brouwer-Visser, J.
Qin, Q.
Davis, J.
Uldrick, T.
Peterman, M.
Miller, E.
Zhu, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S65 - S65
[6] TRANSLATIONALFINDINGSFROM THE ONGOINGFIRST--IN--HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER: REGIMEN SELECTION.
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer--Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S46 - S46
[7] A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer
Van Nieuwenhuysen, Els
Bouberhan, Sara
Papadimitriou, Konstantinos
Arend, Rebecca Christian
Lee, Jung-Yun
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
You, Benoit
Martin, Antonio Gonzalez
Michels, Judith
Mileshkin, Linda R.
Lee, Yeh Chen
Miller, Rowan
Yoo, Suk-Young
Peterman, Mary Jane
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer-Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S59 - S59
[9] A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update
Liu, Joyce
O'Malley, David
Van Nieuwenhuysen, Els
O'Cearbhaill, Roisin
Bouberhan, Sara
Moore, Kathleen
Hou, June
Hamilton, Erika
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
GYNECOLOGIC ONCOLOGY, 2024, 190 : S284 - S284

← 1 →